BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31727117)

  • 1. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
    Póti Á; Gyergyák H; Németh E; Rusz O; Tóth S; Kovácsházi C; Chen D; Szikriszt B; Spisák S; Takeda S; Szakács G; Szallasi Z; Richardson AL; Szüts D
    Genome Biol; 2019 Nov; 20(1):240. PubMed ID: 31727117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
    Maeda J; Haskins JS; Kato TA
    Mutat Res; 2023; 826():111815. PubMed ID: 36812659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    Gulhan DC; Lee JJ; Melloni GEM; Cortés-Ciriano I; Park PJ
    Nat Genet; 2019 May; 51(5):912-919. PubMed ID: 30988514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions.
    Zámborszky J; Szikriszt B; Gervai JZ; Pipek O; Póti Á; Krzystanek M; Ribli D; Szalai-Gindl JM; Csabai I; Szallasi Z; Swanton C; Richardson AL; Szüts D
    Oncogene; 2017 Feb; 36(6):746-755. PubMed ID: 27452521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
    McCabe N; Turner NC; Lord CJ; Kluzek K; Bialkowska A; Swift S; Giavara S; O'Connor MJ; Tutt AN; Zdzienicka MZ; Smith GC; Ashworth A
    Cancer Res; 2006 Aug; 66(16):8109-15. PubMed ID: 16912188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
    Gottipati P; Vischioni B; Schultz N; Solomons J; Bryant HE; Djureinovic T; Issaeva N; Sleeth K; Sharma RA; Helleday T
    Cancer Res; 2010 Jul; 70(13):5389-98. PubMed ID: 20551068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    Hamid AB; Frank LE; Bouley RA; Petreaca RC
    PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
    Polak P; Kim J; Braunstein LZ; Karlic R; Haradhavala NJ; Tiao G; Rosebrock D; Livitz D; Kübler K; Mouw KW; Kamburov A; Maruvka YE; Leshchiner I; Lander ES; Golub TR; Zick A; Orthwein A; Lawrence MS; Batra RN; Caldas C; Haber DA; Laird PW; Shen H; Ellisen LW; D'Andrea AD; Chanock SJ; Foulkes WD; Getz G
    Nat Genet; 2017 Oct; 49(10):1476-1486. PubMed ID: 28825726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 17. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
    Gröschel S; Hübschmann D; Raimondi F; Horak P; Warsow G; Fröhlich M; Klink B; Gieldon L; Hutter B; Kleinheinz K; Bonekamp D; Marschal O; Chudasama P; Mika J; Groth M; Uhrig S; Krämer S; Heining C; Heilig CE; Richter D; Reisinger E; Pfütze K; Eils R; Wolf S; von Kalle C; Brandts C; Scholl C; Weichert W; Richter S; Bauer S; Penzel R; Schröck E; Stenzinger A; Schlenk RF; Brors B; Russell RB; Glimm H; Schlesner M; Fröhling S
    Nat Commun; 2019 Apr; 10(1):1635. PubMed ID: 30967556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
    Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
    Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.